期刊
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY
卷 9, 期 -, 页码 113-117出版社
SAGE PUBLICATIONS LTD
DOI: 10.4137/CMC.S26624
关键词
dyslipidemia; review; hyperlipidemia; cholesterol; HDL; HDL-C; LDL; monoclonal antibody; PCSK; PCSK9; proprotein; convertase; sublisin; kexin; statin; heart attack; myocardial infarction; low HDL; high density lipoprotein; HDL subclass; Biosynthesis; storage; elimination; paraoxonase-1; PON1; platelet activating factor; acetylhydrolase; PAF-AH; apolipoprotein; Apo; ApoA-I; ApoA-II; CETP; niacin; TRIUMPH; AIM-HIGH; HP2-THRIVE; endothelial lipase gene; LIPG; atheroprotective; alirocumab; praluent; evolocumab; repatha; ODYSSEY; OSLER
Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
